Literature DB >> 23485625

More sound cancer therapy biomarker development with active noise control.

Michael L Maitland1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23485625      PMCID： PMC3607516          DOI： 10.1634/theoncologist.2013-0030

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  24 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Authors:  Dirk Strumberg; Heike Richly; Ralf A Hilger; Norbert Schleucher; Sonke Korfee; Mitra Tewes; Markus Faghih; Erich Brendel; Dimitris Voliotis; Claus G Haase; Brian Schwartz; Ahmad Awada; Rudolf Voigtmann; Max E Scheulen; Siegfried Seeber
Journal:  J Clin Oncol       Date:  2004-12-21       Impact factor: 44.544

Review 3.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer.

Authors:  Rakesh K Jain; Dan G Duda; Jeffrey W Clark; Jay S Loeffler
Journal:  Nat Clin Pract Oncol       Date:  2006-01

4.  Mechanisms of hypertension associated with BAY 43-9006.

Authors:  Maria Luisa Veronese; Ari Mosenkis; Keith T Flaherty; Maryann Gallagher; James P Stevenson; Raymond R Townsend; Peter J O'Dwyer
Journal:  J Clin Oncol       Date:  2006-01-30       Impact factor: 44.544

5.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Authors:  Sandrine Faivre; Catherine Delbaldo; Karina Vera; Caroline Robert; Stéphanie Lozahic; Nathalie Lassau; Carlo Bello; Samuel Deprimo; Nicoletta Brega; Giorgio Massimini; Jean-Pierre Armand; Paul Scigalla; Eric Raymond
Journal:  J Clin Oncol       Date:  2005-11-28       Impact factor: 44.544

6.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

7.  VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.

Authors:  Dan G Duda; Tracy T Batchelor; Christopher G Willett; Rakesh K Jain
Journal:  Trends Mol Med       Date:  2007-04-25       Impact factor: 11.951

8.  A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.

Authors:  Melody A Cobleigh; Virginia K Langmuir; George W Sledge; Kathy D Miller; Latrice Haney; William F Novotny; James D Reimann; Amy Vassel
Journal:  Semin Oncol       Date:  2003-10       Impact factor: 4.929

Review 9.  Noise exposure and public health.

Authors:  W Passchier-Vermeer; W F Passchier
Journal:  Environ Health Perspect       Date:  2000-03       Impact factor: 9.031

Review 10.  Overview of biomarkers and surrogate endpoints in drug development.

Authors:  John A Wagner
Journal:  Dis Markers       Date:  2002       Impact factor: 3.434
View more
  1 in total

1.  Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.

Authors:  S Karovic; Y Wen; T G Karrison; G L Bakris; M R Levine; L K House; K Wu; V Thomeas; M A Rudek; J J Wright; E E W Cohen; G F Fleming; M J Ratain; M L Maitland
Journal:  Clin Pharmacol Ther       Date:  2014-03-17       Impact factor: 6.875
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.